Shareholders' equity · 2014–2025
Ascendis Pharma shareholders' equity
−$191M−$81.5M · FY2025
Ascendis Pharma (ASND) reported −$191M in shareholders' equity for fiscal 2025, −$81.5M from the year before.
| Fiscal year | Shareholders' equity | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | −$191M | −$81.5M | Open → |
| FY20242024-12-31 | −$110M | +$51.2M | Open → |
| FY20232023-12-31 | −$161M | −$442M | Open → |
| FY20222022-12-31 | $281M | −71.9% | Open → |
| FY20212021-12-31 | $1.0B | −2.8% | Open → |
| FY20202020-12-31 | $1.0B | +53.4% | Open → |
| FY20192019-12-31 | $671M | +109.2% | Open → |
| FY20182018-12-31 | $321M | +42.8% | Open → |
| FY20172017-12-31 | $225M | +20.6% | Open → |
| FY20162016-12-31 | $186M | +42.1% | Open → |
| FY20152015-12-31 | $131M | +135.5% | Open → |
| FY20142014-12-31 | $55.6M | — | Open → |
Shareholders' equity — Shareholders' equity is what remains after subtracting liabilities from assets — the accounting book value of the company, not its market value.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026
Figures are reported under IFRS in EUR and converted to US dollars at ECB reference rates — fiscal 2025 average 0.885 EUR/$ for income items, year-end 0.851 EUR/$ for balance-sheet items.
Shareholders' equity at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ascendis Pharma shareholders' equity |url=https://companiesranked.com/en/company/ascendis-pharma/shareholders-equity |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ascendis Pharma shareholders' equity. CompaniesRanked. https://companiesranked.com/en/company/ascendis-pharma/shareholders-equityBibTeX
@misc{companiesranked-en-company-ascendis-pharma-shareholders-equity-2026,
author = {{CompaniesRanked}},
title = {{Ascendis Pharma shareholders' equity}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ascendis-pharma/shareholders-equity}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001193125-26-046590 · February 11, 2026
{{cite web |title=Ascendis Pharma shareholders' equity — 20-F (0001193125-26-046590) |url=https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-11}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.